Hims & Hers Expands Platform-Led Access to Provider-Directed Care

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates as an intermediary healthcare platform rather than a direct medical provider, a structure that is central to its business model and regulatory positioning. The company does not practice medicine or employ clinicians to deliver care. Instead, it connects consumers to independent, licensed healthcare providers who retain full responsibility for clinical decision-making, diagnosis and prescribing. Hims & Hers facilitates this interaction through its digital platform by enabling customers to submit health information, connect with licensed providers, manage prescriptions and fulfillment and engage on an ongoing basis, while maintaining a clear separation between platform operations and medical judgment.

This intermediary structure has supported the company’s ability to broaden access across multiple specialties without assuming the role of a medical provider. In recent periods, Hims & Hers has continued to add new provider-led categories such as low testosterone care, menopause and perimenopause support, and expanded diagnostic capabilities, all delivered through licensed third-party clinicians on the platform. These launches are designed around digital intake, at-home testing, and ongoing provider oversight, reinforcing the platform’s role in enabling access rather than delivering care itself. As HIMS invests further in diagnostics, technology, and international expansion, its operating model remains centered on coordinating providers, infrastructure and consumer engagement, while clinical responsibility stays with independent medical professionals.

By positioning itself as a consumer-facing platform that aggregates providers, diagnostics, pharmacies, and manufacturers, Hims & Hers scales access to personalized healthcare while allowing licensed professionals to independently manage patient care. This model underpins both its domestic growth and ongoing international expansion.

GDRX & MED’s Platform-Led Models Expanding Access

GoodRx Holdings, Inc. GDRX operates as an intermediary healthcare platform rather than a direct medical provider, enabling consumers to access prescription savings, cash-pay options and licensed healthcare professionals without practicing medicine itself. GDRX connects consumers, pharmacies and pharmaceutical manufacturers through its digital marketplace, helping reduce friction in medication access and affordability. Recent initiatives, such as expanded pharmacy counter programs and condition-specific telemedicine subscriptions, further reinforce GoodRx’s role as an access and coordination layer within the healthcare ecosystem.

Medifast, Inc. MED operates as an intermediary wellness platform rather than a direct medical provider, delivering habit-based health solutions through its OPTAVIA brand and a network of independent coaches. MED does not provide medical care but facilitates access to lifestyle programs, nutrition plans, and, through collaboration with third-party clinicians, medically supported options when appropriate. Recent developments, including Medifast’s strategic shift toward metabolic health and the introduction of Metabolic Synchronization, reinforce how Medifast coordinates coaching, science-backed products and external clinical access while remaining outside direct care delivery.

HIMS’ Price Performance, Valuation and Estimates

Shares of Hims & Hers have gained 22.4% over the past year, outperforming the industry’s rise of 4.3%.

HIMS’ forward 12-month P/S of 2.60X is lower than the industry’s average of 4.82X and its three-year median of 2.64X. It carries a Value Score of C.

The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.

Hims & Hers currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research